A new trading day began on Monday, with Novavax, Inc (NASDAQ: NVAX) stock price down -4.02% from the previous day of trading, before settling in for the closing price of $9.46. NVAX’s price has ranged from $5.01 to $14.70 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 25.88% over the last five years. Meanwhile, its annual earnings per share averaged 302.71%. With a float of $148.06 million, this company’s outstanding shares have now reached $162.16 million.
The firm has a total of 952 workers. Let’s measure their productivity.
Novavax, Inc (NVAX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Novavax, Inc is 8.84%, while institutional ownership is 58.82%. The most recent insider transaction that took place on May 19 ’25, was worth 75,883. Before that another transaction happened on Apr 14 ’25, when Company’s Former Director proposed sale 4,000 for $6.10, making the entire transaction worth $24,406.
Novavax, Inc (NVAX) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.76 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 302.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.16% during the next five years compared to 25.88% growth over the previous five years of trading.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Here are Novavax, Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.34. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.26, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -0.09 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Analysing the last 5-days average volume posted by the [Novavax, Inc, NVAX], we can find that recorded value of 5.11 million was lower than the volume posted last year of 6.51 million. As of the previous 9 days, the stock’s Stochastic %D was 75.68%.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 67.27%, which indicates a significant increase from 57.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.42 in the past 14 days, which was lower than the 0.43 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.17, while its 200-day Moving Average is $7.64. Now, the first resistance to watch is $9.39. This is followed by the second major resistance level at $9.69. The third major resistance level sits at $9.85. If the price goes on to break the first support level at $8.92, it is likely to go to the next support level at $8.76. Should the price break the second support level, the third support level stands at $8.45.
Novavax, Inc (NASDAQ: NVAX) Key Stats
With a market capitalization of 1.47 billion, the company has a total of 162,422K Shares Outstanding. Currently, annual sales are 682,160 K while annual income is -187,500 K. The company’s previous quarter sales were 239,240 K while its latest quarter income was 106,510 K.
